This study investigates the treatment of patients with fibrosing interstitial lung disease with the investigational drug tezepelumab. The investigational drug has already been approved for the treatment of severe asthma and is being used successfully in this area. The purpose of this study is to investigate how well tezepelumab is tolerated by the patients concerned and whether treatment with tezepelumab also has advantages over standard therapy in the treatment of fibrosing interstitial lung disease. In particular to research the efficacy of Tezepelumab to decrease peripheral blood eosinophilia when compared to placebo after 24 weeks.
